Search alternatives:
point decrease » point increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 point » _ point (Expand Search)
point decrease » point increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 point » _ point (Expand Search)
-
38241
-
38242
-
38243
-
38244
-
38245
EphA3 ectodomain stimulates nasal RGC axon growth in vitro.
Published 2012“…Temporal RGCs did not present any significant change in axon growth on EphA3-Fc between 0.5 and 4 nM and presented a significant decrease at 8 nM (ANOVA and Tukey postest, 3 independent experiments, n: 20 longer axons for explant, 3 explants for condition). …”
-
38246
ATRA treatment induces expression of S100 and inhibits PMP22 expression.
Published 2017“…<p>Flow cytometry analysis (FACS) of S100 and PMP22 protein expression in ATRA treated MPNST cells on day 7 of treatment (5μM). Bars indicate increase or decrease of fluorescence intensity (%) compared to untreated controls (100%). …”
-
38247
-
38248
-
38249
-
38250
-
38251
-
38252
-
38253
-
38254
-
38255
-
38256
Diabetes, Drug Treatment and Mortality in COVID-19: A Multinational Retrospective Cohort Study
Published 2021“…Glucose-regulating medications such as glucagon-like peptide-1 receptor (GLP-1R) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and pioglitazone are known to have anti-inflammatory effects that may improve outcomes in patients with SARS-CoV-2 infection. In a multinational retrospective cohort study, we used the TriNetX COVID-19 Research Network of 56 large healthcare organizations to examine these medications in relation to the incidence of hospital admissions, respiratory complications, and mortality within 28 days following a COVID-19 diagnosis. …”
-
38257
-
38258
-
38259
-
38260